Guan used rAd-p53, combined with chemotherapeutic drugs, to treat advanced NSCLC via bronchial arterial access in a controlled clinical trial, and the results showed that the combined group witnessed a longer time without progression (p = 0.018), but survival analysis showed no statistical difference (p = 0.224) [25]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.